Skip to main content

Advertisement

SpringerLink
Log in

Endothelial dysfunction and the metabolic syndrome

  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

Abstract

The metabolic syndrome is a highly prevalent multifaceted clinical entity produced through the interaction of genetic, hormonal, and lifestyle factors. A distinctive constellation of abnormalities precedes and predicts the accelerated development of atherogenesis and type 2 diabetes mellitus. Abnormalities of inflammation and coagulation represent emerging risk contributors associated with obesity and insulin resistance, central components of the metabolic syndrome, which act in concert with traditional abnormalities to increase cardiovascular risk. The initiation and progression of atherosclerosis may have its origins in impaired endothelial function that can be detected at the earliest stages of development of the syndrome. The basic elements of the metabolic syndrome and accelerated phase of atherogenesis are often silent partners that present many years before the onset of type 2 diabetes mellitus. The ability to detect and monitor subclinical vascular disease, as a reflection of the multiple factors that contribute to impair arterial wall integrity, holds potential to further refine cardiovascular risk stratification. Noninvasive assessment of vascular health may also aid the clinical decision-making process by guiding therapeutic interventions to optimize vascular protection in the metabolic syndrome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Zimmet P, Boyko EJ, Collier GR, de Courten M: Etiology of the metabolic syndrome: potential role of insulin resistance, leptin resistance, and other players. Ann N Y Acad Sci 1999, 892:25–44.

    Article  PubMed  CAS  Google Scholar 

  2. Yip J, Facchini FS, Reaven GM: Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease. J Clin Endocrinol Metab 1998, 83:2773–2776.

    Article  PubMed  CAS  Google Scholar 

  3. Isomaa B, Almgren P, Tuomi T, et al.: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001, 24:683–689.

    Article  PubMed  CAS  Google Scholar 

  4. Depr’es J-P, Lemieu I, Prud’homme D: Treatment of obesity: need to focus on abdominally obese patients. BMJ 2001, 322:716–720.

    Article  Google Scholar 

  5. Reaven GM: Role of insulin resistance in human disease. Diabetes 1988, 37:1595–1607.

    Article  PubMed  CAS  Google Scholar 

  6. Meigs JB: Invited commentary: insulin resistance syndrome? Syndrome X? Multiple metabolic syndrome? A syndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors. Am J Epidemiol 2000, 152:908–911.

    Article  PubMed  CAS  Google Scholar 

  7. Grundy SM: Obesity, metabolic syndrome and coronary atherosclerosis. Circulation 2002, 105:2696–2698. Overview presenting data linking obesity and components of the metabolic syndrome and accelerated development of cardiovascular disease.

    Article  PubMed  Google Scholar 

  8. Sakkinen PA, Wahl P, Cushman M, et al.: Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol 2002, 152:897–907.

    Article  Google Scholar 

  9. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation. Diabet Med 1998, 15:539–553.

    Article  PubMed  CAS  Google Scholar 

  10. Cefalu WT: Insulin resistance: cellular and clinical concepts. Exp Biol Med (Maywood) 2001, 226:13–26.

    CAS  Google Scholar 

  11. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [no authors listed]. JAMA 2001, 285:2486–2497.

  12. Ford SE, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults. JAMA 2002, 287:356–359.

    Article  PubMed  Google Scholar 

  13. Keys A, Menotti A, Aravanis C, et al.: The seven countries study: 2289 deaths in 15 years. Prev Med 1984, 13:141–154.

    Article  PubMed  CAS  Google Scholar 

  14. Wilson PWF, D’Agostino RB, Levy D, et al.: Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97:1837–1847.

    PubMed  CAS  Google Scholar 

  15. Rimm EB, Stampfer MJ, Giovannucci E, et al.: Body Size and fat distribution as predictors of coronary heart disease among middle-aged and older US men. Am J Epidemiol 1995, 141:1117–1127.

    PubMed  CAS  Google Scholar 

  16. Tracy RP: Is visceral adiposity the "enemy within"? Arterioscler Thromb Vasc Biol 2001, 21:881–883.

    PubMed  CAS  Google Scholar 

  17. Smiley T, Oh P, Shane LG, et al.: The relationship of insulin resistance measured by reliable indexes to coronary artery disease risk factors and outcomes: a systemic review. Can J Cardiol 2001, 17:797–805.

    PubMed  CAS  Google Scholar 

  18. Lemieux I, Pascot A, Prud’homme D, et al.: Elevated C-reactive protein another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol 2001, 21:961–967.

    PubMed  CAS  Google Scholar 

  19. Schmidt MI, Duncan BB, Sharett AR, et al.: Markers of inflammation and prediction of diabetes mellitus in adults. (Atherosclerosis Risk In Communities study): a cohort study. Lancet 1999, 353:1649–1652.

    Article  PubMed  CAS  Google Scholar 

  20. Das UN: Obesity, metabolic syndrome X and inflammation. Nutrition 2002, 18:430–438.

    Article  PubMed  CAS  Google Scholar 

  21. Cermak J, Key N, Bach R, et al.: C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993, 82:513–520.

    PubMed  CAS  Google Scholar 

  22. Lee RT, Libby P: The unstable atheroma. Arterioscler Thromb Vasc Biol 1997, 17:1859–1867.

    PubMed  CAS  Google Scholar 

  23. Blake GJ, Ridker PM: Novel clinical markers of vascular inflammation. Circ Res 2001, 89:763–771.

    PubMed  CAS  Google Scholar 

  24. Loskutoff DJ, Samad F: The adipocyte and hemostatic balance in obesity: studies of PAI-1. Arterioscler Thromb Vasc Biol 1998, 18:1–6.

    PubMed  CAS  Google Scholar 

  25. Blake GJ, Ridker PM, Kuntz KM: Projected life-expectancy gains with statin therapy for individuals with elevated Creactive protein levels. J Am Coll Cardiol 2002, 40:49–55.

    Article  PubMed  CAS  Google Scholar 

  26. Calles-Escandon J, Cipolla M: Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev 2001, 22:36–52.

    Article  PubMed  CAS  Google Scholar 

  27. Anderson TJ: Assessment and treatment of endothelial dysfunction in humans. J Am Coll Cardiol 1999, 34:631–638.

    Article  PubMed  CAS  Google Scholar 

  28. Verma S, Anderson TJ: Fundamentals of endothelial function for the clinical cardiologist. Circulation 2002, 105:546–549.

    Article  PubMed  CAS  Google Scholar 

  29. Vallance P, Chan N: Endothelial function and nitric oxide: clinical relevance. Heart 2001, 85:342–350.

    Article  PubMed  CAS  Google Scholar 

  30. Lüscher TF, Noll G: Endothelial function as an end-point in international trials: concepts, methods and current data. J Hypertens 1996, 145:S111-S121.

    Article  Google Scholar 

  31. Schüchinger Britten MB, Zeiher AM: Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000, 101:1899–1906.

    Google Scholar 

  32. Drexter H: Endothelium as a therapeutic target in heart failure. Circulation 1998, 98:2652–2655.

    Google Scholar 

  33. Balletshofer BM, Rittig K, Enderle MD, et al.: Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation 2000, 101:1780–1784.

    PubMed  CAS  Google Scholar 

  34. Tounian P, Aggoun Y, Dubern B, et al.: Presence of increased stiffness of the common carotid artery and endothelial dysfunction in severely obese children: a prospective study. Lancet 2001, 358:1400–1404. Important study describing a link between severe obesity in children and the presence of endothelial dysfunction and increased arterial stiffness, which may have consequences for the future development of atherosclerosis.

    Article  PubMed  CAS  Google Scholar 

  35. Yudkin JS, Stehouwer CDA, Emeis JJ, Coppack SW: C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction. Arterioscler Thromb Vasc Biol 1999, 19:972–978.

    PubMed  CAS  Google Scholar 

  36. Festa A, D’Agostino R, Howard G, et al.: Chronic subclinical inflammation as part of the insulin resistance syndrome. The insulin resistance atherosclerosis study (IRAS). Circulation 2000, 102:42–47.

    PubMed  CAS  Google Scholar 

  37. Cai H, Harrison DG: Endothelial dysfunction and cardiovascular diseases. The role of oxidant stress. Circ Res 2000, 87:840–844.

    PubMed  CAS  Google Scholar 

  38. Gopaul NK, Manraj MD, Hebe A, et al.: Oxidative stress could precede endothelial dysfunction and insulin resistance in Indian Mauritians with impaired glucose metabolism. Diabetologia 2001, 44:706–712.

    Article  PubMed  CAS  Google Scholar 

  39. Perticone F, Ceravolo R, Candigliota M, et al.: Obesity and body fat distribution induce endothelial dysfunction by oxidative stress: protective effect of vitamin C. Diabetes 2001, 50:159–165. Indirect evidence that vascular oxidative stress contributes to endothelial dysfunction in human obesity. Vitamin C improved but did not fully correct the blunted responses to acetylcholine.

    Article  PubMed  CAS  Google Scholar 

  40. Vaccarino V, Halford TR, Krumholz HM: Pulse pressure and risk for myocardial infarction and heart failure in the elderly. J Am Coll Cardiol 2000, 30:130–138.

    Article  Google Scholar 

  41. McVeigh GE, Bratteli CW, Morgan DJ, et al.: Age-related abnormalities in arterial compliance identified by pressure pulse contour analysis. Hypertension 1999, 33:1392–1398.

    PubMed  CAS  Google Scholar 

  42. Cohn JN, Finkelstein S, McVeigh GE, et al.: Non-invasive pulse wave analysis for the early detection of vascular disease. Hypertension 1995, 26:503–508.

    PubMed  CAS  Google Scholar 

  43. McVeigh GE, Allen PB, Morgan DJ, et al.: Nitric oxide modulation of blood vessel tone identified by arterial waveform analysis. Clin Sci 2001, 100:387–393.

    Article  PubMed  CAS  Google Scholar 

  44. Haffner SM, Stern MP, Hazuda HP, et al.: Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990, 263:2893–2898.

    Article  PubMed  CAS  Google Scholar 

  45. Abate N: Obesity and cardiovascular disease: pathogenic role of the metabolic syndrome and therapeutic implications. J Diabetes Complications 2000, 14:154–174.

    Article  PubMed  CAS  Google Scholar 

  46. MacMahon S: Blood pressure and the risk of cardiovascular disease. N Engl J Med 2000, 342:50–51.

    Article  PubMed  CAS  Google Scholar 

  47. Grundy SM, Howard B, Smith S Jr, et al.: Prevention Conference VI: Diabetes and Cardiovascular Disease: executive summary: conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation 2002, 105:2231–2239.

    Article  PubMed  Google Scholar 

  48. McVeigh GE, Hamilton PK, Morgan J: Evaluation of mechanical arterial properties: clinical, experimental and therapeutic aspects. Clin Sci 2002, 102:51–67. Comprehensive overview of techniques employed to evaluate the mechanical properties of arteries that hold potential to refine cardiovascular risk stratification and guide therapeutic interventions to optimize cardiovascular protection.

    Article  PubMed  Google Scholar 

  49. Lavrencic A, Guzic Salobir B, Keber I: Physical training improves flow-mediated dilation in patients with the polymetabolic syndrome. Arterioscler Thromb Vasc Biol 2000, 20:551–555.

    PubMed  CAS  Google Scholar 

  50. Stühlinger MC, Abbasi F, Chu JW, et al.: Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002, 287:1420–1426. Mechanistic study demonstrating a link between insulin resistance and plasma concentrations of an endogenous nitric oxide synthase inhibitor, assymmetric dimethylarginine. Pharmacologic intervention with rosiglitazone enhanced insulin sensitivity and decreased assymmetric dimethylarginine levels.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiovascular Division, University of Minnesota, 420 Delaware Street SE, Mayo Mail Code 508, 55455, Minneapolis, MN, USA

    Gary E. McVeigh MD & Jay N. Cohn MD

Authors
  1. Gary E. McVeigh MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jay N. Cohn MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

McVeigh, G.E., Cohn, J.N. Endothelial dysfunction and the metabolic syndrome. Curr Diab Rep 3, 87–92 (2003). https://doi.org/10.1007/s11892-003-0059-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11892-003-0059-0

Keywords

Search

Navigation